On April 25th, 2012, Reuters reported that Avandia sales are collapsing as the drug has been linked to heart risks. Avandia, a popular drug manufactured by GlaxoSmithKline, was first approved by the FDA in 1999 to treat Type 2 diabetes in adult patients. GlaxoSmithKline’s first-quarter 2012 sales on the metabolic sector are down 60 percent to £33 million, as Avandia (rosiglitazone) product sales slumped following virtual market removal of the diabetes treatment on safety issues. Several lawsuits have been filed on Avandia side effects.
According to court documents, on September 7th, 2011, two plaintiffs, LeMario Holton of Illinois and Rita Catherine Rieger of Delaware, filed a lawsuit in St. Clair County (case no. 11-L-501) alleging they suffered heart attacks and congestive heart failure from their ingestion of Avandia to treat Type 2 diabetes. Plaintiffs claim that they had already begun taking Avandia before warnings of the potential increased risk of heart failure and myocardial ischemia were added to the label in 2007.
In May 2007, the New England Journal of Medicine published an independent review of the 2005 clinical data revealing an increase of 43 percent in the risk of heart attacks and an increase of over 60 percent in the risk of cardiovascular death associated with the use of Avandia.
AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of Avandia severe adverse events, someone can easily and inexpensively deal with it. As Mr. Burke, director of media relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Avandia remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”
On September 23rd, 2010 the U.S. Food and Drug Administration announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia.